DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22433/S-010

SUPPLEMENT APPROVAL

AstraZeneca LP
ATTENTION: Pat Patterson
Director, Regulatory Affairs
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803

Dear Ms. Patterson:

Please refer to your Supplemental New Drug Application (sNDA) dated June 13, 2013, received June 13, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for BRILINTA (ticagrelor) 90 mg Tablets.

This Prior Approval supplemental new drug application provides clinical pharmacology information on ticagrelor as well as the impact of BRILINTA on the pharmacokinetics of cyclosporine.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. These changes are as follows:

- Under Section 7, **DRUG INTERACTIONS**, subsection Effects on Other Drugs, the following sentence was added:

  "Ticagrelor is also a p-glycoprotein (P-gp) substrate."

- In Section 12, **CLINICAL PHARMACOLOGY**, subsection 12.3 (**Pharmacokinetics**), the following changes were made:

  - Under "Effects of Other Drugs on BRILINTA", the following sentence was added:

    "P-gp inhibitors (e.g. cyclosporine) increase ticagrelor exposure."

  - Under "Effects of BRILINTA on Other Drugs", pharmacokinetics data on cyclosporine was added.

- In addition to the above changes, other editorial edits were made throughout the label.

We note that your June 13, 2013, submission includes final printed labeling (FPL) for your package insert and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the

wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions indicated above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact:

Alison Blaus, RAC
Regulatory Project Manager
(301) 796-1138

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ALISON L BLAUS
12/13/2013

MARY R SOUTHWORTH
12/13/2013